# Capra Biosciences

> Modular biomanufacturing for chemicals and pharmaceutical ingredients.

## Why it is interesting

Capra's model combines biological production with reactor engineering and facility operations. Its commercial milestones include repeatable product quality, scale-up, customer qualification and the ability to supply molecules reliably within domestic supply chains.

## Profile

- **Latest funding:** Pre-Seed — $1.8M (June 6, 2022)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $1.8M
- **Stage:** N/A
- **Status:** private
- **Industries:** biotech-life-sciences, climate-tech, deep-tech
- **Coverage:** full
- **Last updated:** 2026-11-15
- **Latest funding investors:** Prithvi Ventures, E14 Fund, GS Futures, Wes Osbourn, Savantus Ventures, Asymmetry Ventures, Decarbonization Consortium, SOSV

## Key facts

- Prithvi is named in the June 6, 2022 $1.8M pre-seed announcement.
- Platform combines biological production with modular continuous reactors.
- Government project funding is tracked separately from venture equity.

## Funding history

- Pre-Seed · $1.8M · June 6, 2022
  Source: https://pwcded.org/news/capra-biosciences-raises-1-8m-in-pre-seed-round-for-renewable-chemical-innovations/

## Investors in our directory

- https://venturecapitaltracker.com/fund/prithvi-ventures

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/capra-biosciences
